Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis

This is a study of allogeneic stem cell transplantation with TBX-2400 in adult subjects with Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF).

The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way.

This study has two goals. The first goal is to find out if transplant with TBX-2400 is safe. The second goal is to find out what effects TBX-2400 stem cells have on time to engraftment in adult subjects with AML or MF.

The study hypothesis is that TBX-2400 cells will shorten the time to immune reconstitution after transplant.

Study Overview

• Status: Not yet recruiting
• Conditions: Myelofibrosis; Acute Myelogenous Leukemia
• Intervention / Treatment: Biological: TBX-2400

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Vivienne Margolis, B.Sc; Phone Number: +972-4639634; Email: vmargolis@taigabiotech.com
• Study Contact Backup: Name: Yosef Refaeli, Ph.D; Phone Number: +1-720-859-3547; Email: refaeli@taigabiotech.com

Study Locations

• Croatia
  • Zagreb, Croatia, 10000
    • University Hospital Centre Zagreb
    • Contact: Nadira Durakovic, MD, PhD; Phone Number: +385-989611829; Email: nadira.durakovic@mef.hr
    • Principal Investigator: Nadira Durakovic, MD, PhD
• Italy
  • Roma, Italy, 00168
    • Fondazione Policlinico Universitario Agostino Gemelli
    • Contact: Simona Sica, MD; Phone Number: TBA; Email: Simona.sica@unicatt.it
    • Principal Investigator: Simona Sica, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. For crAML: AML with ≥5% blasts (either by morphology or by multi-parameter flow cytometry [MFC]) in a marrow aspirate obtained within 21 days of enrollment in the trial, and following the administration of at least two prior courses of chemotherapy;
2. For MF: primary MF or MF that has progressed from a myeloproliferative disease. Dynamic International Prognostic Scoring System (DIPSS)-plus to be utilized to support the inclusion of MF subjects at screening;
3. Subject undergoing allogeneic stem cell transplantation on the decision of transplanting physician;
4. Signed informed consent of donor and recipient;
5. Subjects of ≥ 18 years of age (no upper age limit);
6. Donor agrees to donate bone marrow-derived or mobilized peripheral blood stem cells;
7. Subjects with Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2;
8. Adequate pulmonary function with Diffusing Capacity for Carbon Monoxide (DLCO) > 50;
9. Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception (e.g. sterilization, hormone implants, hormone injections, intrauterine devices, or vasectomized partner with combined use of condom and/or birth control pills) from screening until 6 months after TBX-2400 transplantation;
10. Able to adhere to all trial treatments and procedures.

Exclusion Criteria:

1. Previous stem cell transplantation;
2. For MF: Blasts > 10% in a marrow aspirate obtained within 30 days of screening;
3. Renal function: serum creatinine > 1.5 x Upper Limit of Normal (ULN);
4. Hepatic function: impaired synthetic function as indicated by a serum fibrinogen below the normal limit. Aspartate transaminase/alanine transaminase (AST/ALT) > 3.0 x ULN. Bilirubin, > 1.5 x ULN;
5. Cardiac function: ejection fraction < 45% as determined by echocardiography;
6. Prior malignancy active within previous three years - except for locally curable cancers such as cutaneous basal or squamous cell cancer, superficial bladder cancer, carcinoma in situ of cervix or breast, or carcinoma in situ of the prostate;
7. Positive pregnancy test or breastfeeding for women of childbearing age;
8. Serologic evidence of chronic Hepatitis B virus infection or Hepatitis C exposure;
9. Known history of positive test for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS);
10. Hypersensitivity to any trial medication (including the preparative regimen, TBX-2400 treatment and any prophylaxis or other medication planned);
11. Presence of a serious or uncontrolled medical disorder that, in the opinion of the Investigator, may increase the risk associated with trial participation or trial drug administration, impair the ability of the participant to receive protocol therapy, or interfere with interpretation of trial results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TBX-2400 treatment; Single intravenous infusion of TBX-2400	Biological: TBX-2400; Hematopoietic stem cells transplantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events according to NCI-CTCAE Version 5.0	Adverse events from subject reporting or other assessments	Two years
Transplant engraftment	Assessment of transplant engraftment will include absolute neutrophil count, untransfused platelet count and donor chimerism	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immune reconstitution as measured by CD3+ cell count	Immune reconstitution as measured by CD3+ cell count > 300/μL	Up to Day 360
Immunoglobulin (IgA) levels		Up to Day 360
Immunoglobulin (IgM) levels		Up to Day 360
T-cell Engraftment	CD45 RA versus RO at 3, 6, 9 and 12 months	Up to Day 360
Disease-free survival		Two years
Incidence of secondary graft failure		Two years
Transplant-Related Mortality (TRM)		100 Days
Quality of life using the World Health Organisation Five Wellbeing Index	QoL assessed at 3, 6, 9 and 12 months (World Health Organization [WHO] Five Wellbeing Index).	Up to day 360

Collaborators and Investigators

• Sponsor: Taiga Biotechnologies, Inc.
• Investigators: Principal Investigator: Andrea Bacigalupo, MD, Unit for Hematology and BMT, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2022
• Primary Completion (Anticipated): August 28, 2024
• Study Completion (Anticipated): October 28, 2024

Study Registration Dates

• First Submitted: January 12, 2021
• First Submitted That Met QC Criteria: January 12, 2021
• First Posted (Actual): January 14, 2021

Study Record Updates

• Last Update Posted (Actual): May 3, 2022
• Last Update Submitted That Met QC Criteria: May 1, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Acute Myeloid Leukemia; Myelofibrosis; Leukemia; Allogeneic stem cell transplant; Acute Myelogenous Leukemia; Bone Marrow Transplant; Bone Marrow Cancer; Primary myelofibrosis; Myeloproliferative disorders
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Bone Marrow Diseases; Hematologic Diseases; Myeloproliferative Disorders; Primary Myelofibrosis; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute
• Other Study ID Numbers: TBX-2400-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No